Advertisement
Screener

ORCHARD THERAPEUTICS PLC Operating Income

ORCHARD THERAPEUTICS PLC Operating Income

ORCHARD THERAPEUTICS PLC reported Operating Income of -$21.61 million for the 3-month period ending 2023-09-30, per its 10-Q filed 2023-11-13.

Discontinued › Income Statement

us-gaap:OperatingIncomeLoss · last filed 2023-11-13

  • ORCHARD THERAPEUTICS PLC operating income (loss) for the quarter ending 2023-09-30 was -$21.61M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for the quarter ending 2023-06-30 was -$22.56M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for the quarter ending 2023-03-31 was -$26.26M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for the quarter ending 2022-12-31 was -$31.59M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for fiscal 2022 was -$127.09M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for fiscal 2021 was -$140.43M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for fiscal 2020 was -$156.98M.
  • ORCHARD THERAPEUTICS PLC operating income (loss) for fiscal 2019 was -$172.87M.
Period endOperating Income (Loss) 3 monthOperating Income (Loss) 6 monthOperating Income (Loss) 9 monthOperating Income (Loss) 12 month
2023-09-30-$21.61M
10-Q · filed 2023-11-13
-$44.17M
derived: sum of 2 quarters · filed 2023-11-13
-$70.42M
10-Q · filed 2023-11-13
-$102.02M
derived: sum of 4 quarters · filed 2023-11-13
2023-06-30-$22.56M
10-Q · filed 2023-08-10
-$48.82M
10-Q · filed 2023-08-10
-$80.41M
derived: sum of 3 quarters · filed 2023-08-10
-$105.88M
derived: sum of 4 quarters · filed 2023-11-13
2023-03-31-$26.26M
10-Q · filed 2023-05-15
-$57.85M
derived: sum of 2 quarters · filed 2023-05-15
-$83.32M
derived: sum of 3 quarters · filed 2023-11-13
-$115.77M
derived: sum of 4 quarters · filed 2023-11-13
2022-12-31-$31.59M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
-$57.06M
derived: sum of 2 quarters · filed 2023-11-13
-$89.51M
derived: sum of 3 quarters · filed 2023-11-13
-$127.09M
10-K · filed 2023-03-14
2022-09-30-$25.47M
10-Q · filed 2023-11-13
-$57.92M
derived: sum of 2 quarters · filed 2023-11-13
-$95.50M
10-Q · filed 2023-11-13
-$131.91M
derived: sum of 4 quarters · filed 2023-11-13
2022-06-30-$32.45M
10-Q · filed 2023-08-10
-$70.03M
10-Q · filed 2023-08-10
-$106.44M
derived: sum of 3 quarters · filed 2023-08-10
-$139.36M
derived: sum of 4 quarters · filed 2023-08-10
2022-03-31-$37.58M
10-Q · filed 2023-05-15
-$74.00M
derived: sum of 2 quarters · filed 2023-05-15
-$106.91M
derived: sum of 3 quarters · filed 2023-05-15
-$142.93M
derived: sum of 4 quarters · filed 2023-05-15
2021-12-31-$36.41M
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-14
-$69.33M
derived: sum of 2 quarters · filed 2023-03-14
-$105.35M
derived: sum of 3 quarters · filed 2023-03-14
-$140.43M
10-K · filed 2023-03-14
2021-09-30-$32.92M
10-Q · filed 2022-11-14
-$68.93M
derived: sum of 2 quarters · filed 2022-11-14
-$104.02M
10-Q · filed 2022-11-14
-$142.89M
derived: sum of 4 quarters · filed 2022-11-14
2021-06-30-$36.01M
10-Q · filed 2022-08-04
-$71.10M
10-Q · filed 2022-08-04
-$109.97M
derived: sum of 3 quarters · filed 2022-08-04
-$136.28M
derived: sum of 4 quarters · filed 2022-08-04
2021-03-31-$35.09M
10-Q · filed 2022-05-12
-$73.96M
derived: sum of 2 quarters · filed 2022-05-12
-$100.26M
derived: sum of 3 quarters · filed 2022-05-12
-$147.08M
derived: sum of 4 quarters · filed 2022-05-12
2020-12-31-$38.87M
10-K · filed 2021-03-02
-$65.18M
derived: sum of 2 quarters · filed 2021-11-04
-$112.00M
derived: sum of 3 quarters · filed 2021-11-04
-$156.98M
10-K · filed 2022-03-30
2020-09-30-$26.30M
10-Q · filed 2021-11-04
-$73.12M
derived: sum of 2 quarters · filed 2021-11-04
-$118.11M
10-Q · filed 2021-11-04
-$167.13M
derived: sum of 4 quarters · filed 2021-11-04
2020-06-30-$46.82M
10-Q · filed 2021-08-04
-$91.80M
10-Q · filed 2021-08-04
-$140.83M
derived: sum of 3 quarters · filed 2021-08-04
-$182.24M
derived: sum of 4 quarters · filed 2021-08-04
2020-03-31-$44.98M
10-Q · filed 2021-05-13
-$94.01M
derived: sum of 2 quarters · filed 2021-05-13
-$135.42M
derived: sum of 3 quarters · filed 2021-05-13
-$189.57M
derived: sum of 4 quarters · filed 2021-05-13
2019-12-31-$49.03M
10-K · filed 2021-03-02
-$90.44M
derived: sum of 2 quarters · filed 2021-03-02
-$144.59M
derived: sum of 3 quarters · filed 2021-03-02
-$172.87M
10-K · filed 2021-03-02
2019-09-30-$41.41M
10-K · filed 2021-03-02
-$95.56M
derived: sum of 2 quarters · filed 2021-03-02
-$123.85M
10-Q · filed 2020-11-03
-$152.68M
derived: sum of 4 quarters · filed 2021-03-02
2019-06-30-$54.15M
10-K · filed 2021-03-02
-$82.44M
10-Q · filed 2020-08-06
-$111.27M
derived: sum of 3 quarters · filed 2021-03-02
-$145.36M
derived: sum of 4 quarters · filed 2021-03-02
2019-03-31-$28.28M
10-K · filed 2021-03-02
-$57.11M
derived: sum of 2 quarters · filed 2021-03-02
-$91.20M
derived: sum of 3 quarters · filed 2021-03-02
-$249.62M
derived: sum of 4 quarters · filed 2021-03-02
2018-12-31-$28.83M
10-K · filed 2020-02-27
-$62.92M
derived: sum of 2 quarters · filed 2020-02-27
-$221.33M
derived: sum of 3 quarters · filed 2020-02-27
-$235.03M
10-K · filed 2020-02-27
2018-09-30-$34.09M
10-K · filed 2020-02-27
-$192.50M
derived: sum of 2 quarters · filed 2020-02-27
-$206.20M
6-K · filed 2019-11-07
2018-06-30-$158.41M
10-K · filed 2020-02-27
-$172.11M
6-K · filed 2019-08-08
2018-03-31-$13.70M
10-K · filed 2020-02-27
2017-12-31-$38.51M
10-K · filed 2020-02-27
2016-12-31-$19.20M
20-F · filed 2019-03-22